Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
Liposomal amphotericin B (LAmB) combined wither either micafungin or deferasirox was synergistic in previous murine studies with mucormycosis or aspergillosis. We hypothesized that triple therapy using LAmB, micafungin, and deferasirox could further improve outcomes of mucormycosis or aspergillosis. Triple therapy improved survival and reduced tissue fungal burden of mice with mucormycosis and to a lesser extent with aspergillosis. Continued investigation into the use of triple therapy against mucormycosis and aspergillosis is warranted.
Los Angeles Biomedical Research Institute, Division of Infectious Diseases, Harbor-UCLA Medical Center, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502, USA. ibrahim@labiomed.org
Ashraf S
AS
Ibrahim
Teclegiorgis
T
Gebremariam
Guanpingsheng
G
Luo
Yue
Y
Fu
Samuel W
SW
French
John E
JE
Edwards
Brad
B
Spellberg
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000472:pathogenicity; D004195:Disease Models, Animal; D054714:Echinocandins / Q000627:therapeutic use*; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D055666:Lipopeptides / Q000627:therapeutic use; D000077551:Micafungin; D051379:Mice; D008807:Mice, Inbred BALB C; D009091:Mucormycosis / Q000188:drug therapy*; D011090:Polyenes / Q000627:therapeutic use*; D012233:Rhizopus / Q000187:drug effects / Q000472:pathogenicity
D000935:Antifungal Agents; D054714:Echinocandins; D007502:Iron Chelating Agents; D055666:Lipopeptides; D011090:Polyenes; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077551:Micafungin
Cancer. 2010 Nov 15;116(22):5290-6
20665889
Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81
11709327
Transpl Infect Dis. 2011 Apr;13(2):182-5
20738831
Antimicrob Agents Chemother. 2005 Feb;49(2):830-2
15673781
J Antimicrob Chemother. 2010 Feb;65(2):289-92
19942619
Antimicrob Agents Chemother. 2009 Aug;53(8):3508-10
19528281
Cancer. 2007 Sep 15;110(6):1303-6
17614303
Int J Antimicrob Agents. 2008 Nov;32 Suppl 2:S103-9
19013332
J Clin Invest. 2007 Sep;117(9):2649-57
17786247
Eur J Clin Microbiol Infect Dis. 2002 Mar;21(3):161-72
11957017
Curr Opin Infect Dis. 2008 Dec;21(6):620-5
18978530
N Engl J Med. 2002 Aug 8;347(6):408-15
12167683
Antimicrob Agents Chemother. 2009 Sep;53(9):4035-9
19596890
Infect Immun. 2005 Sep;73(9):5493-503
16113265
Antimicrob Agents Chemother. 2010 Sep;54(9):3884-94
20606065
Clin Infect Dis. 2008 Aug 1;47(3):364-71
18558882
Clin Infect Dis. 1996 Sep;23(3):608-15
8879787
Antimicrob Agents Chemother. 2009 Jul;53(7):3122-5
19433555
Antimicrob Agents Chemother. 2004 May;48(5):1908-11
15105158
Antimicrob Agents Chemother. 2008 Apr;52(4):1556-8
18212099
Mycopathologia. 2009 Dec;168(6):313-27
19308672
Antimicrob Agents Chemother. 2003 Oct;47(10):3343-4
14506054
Mol Microbiol. 2010 Aug;77(3):587-604
20545847
Antimicrob Agents Chemother. 2005 Feb;49(2):721-7
15673756
Clin Microbiol Rev. 2005 Jul;18(3):556-69
16020690